Quest Diagnostics expands employee SARS-CoV-2 (COVID-19) specimen collection sites
Since March, Quest Diagnostics has been at the forefront of SARS-CoV-2 (COVID-19) testing, working to increase testing capacity and access to molecular (NAAT) tests. In May, Quest rolled out their Return-to-work testing program, which offers both antibody and molecular testing to employers to help reduce the spread of COVID-19 at the workplace.
For molecular testing (the testing that looks for an active infection), employers have a variety of collection methods to choose from to help ensure employees most at risk for COVID-19 can complete a specimen collection. Beginning July 24, another option will be added to the list: observed self-collection at Walmart Neighborhood Market drive-thru pharmacies.
COVID-19 molecular specimen collection methods
Employers now have access to the following collection methods, depending on the unique needs of their organization.
- NEW: Observed self-collection at Walmart® Neighborhood Market drive-thru pharmacies*
- Employees schedule an appointment for observed self-collection
- Date, time, and location restrictions may apply
- Employee drives up to the pharmacy window and completes the observed self-collection
- Pharmacy staff ship specimens to Quest for processing
- By-request unsupervised self-collection
- Employees take a digital questionnaire to determine if they qualify for a self-collection kit
- If they qualify, employees complete the self-collection and ship their specimen back to Quest for processing
- Direct mail unsupervised self-collection*
- Self-collection kits are shipped to employees
- Employees complete the self-collection and ship their specimen back to Quest for processing
- Bulk testing supplies shipment to employer*
- Quest Diagnostics ships bulk molecular testing supplies (deconstructed kits) to employer locations
- Employer collects employee consent and distributes self-collection kits
- Employees complete self-collection under observed collection provided by the employer
- Employer ships specimens back to Quest for processing
- Observed work site self-collection*
- Available for employees at work sites with over 100 employee participants
- Quest providers are on-site to supervise employee self-collection
- Employer must be able to accommodate safety standards for on-site collections as defined by Quest Diagnostics
- Quest staff ships specimens to Quest for processing
*These options are available to employers with 1,000 or more employees.
For more information about our retail specimen collection method for COVID-19 molecular testing, fill in this form or contact your Quest Diagnostics Account Manager.
The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.